ClinicalTrials.gg
RecruitingNCT07940660GPMDBTUpdated Nov 17, 2026

Efficacy and Mechanisms of Change of Two Brief Treatments for Borderline Personality Disorder

An interventional study of Good Psychiatric Management and dialectical behavior therapy in Borderline Personality Disorder and Moderate Personality Disorder, sponsored by University of Lausanne Hospitals. Recruiting at 1 site in Switzerland. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University of Lausanne Hospitals · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
144
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 10 studies in Borderline Personality Disorder with a site in Switzerland — 3 open to participants now, 3 under way, none of them phase 3. Borderline Personality Disorder · Switzerland.

Started
2026
with 2 others
No phase
9 of 10
3 open now
Registered
10th of 10
by date
Lead sponsor
3 of 10
University of Lausanne Hospitals

Among the 10 studies in Borderline Personality Disorder with a site in Switzerland, this one is one of 3 that started in 2026, is one of 9 with no phase, and was the 10th registered.

Borderline Personality Disorder

278 studies on the registry are indexed under Borderline Personality Disorder; 69 are open to participants now.

Browse Borderline Personality Disorder studies →

Open to participants now

3 of the 10 studies in Borderline Personality Disorder with a site in Switzerland are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →

Who these studies take

Of the 48 Borderline Personality Disorder studies recruiting now, 18 (38%) set no upper age limit and 29 (60%) stop at 75 or younger; 7 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Borderline Personality Disorder with a site in Switzerland, or all of them as a file.
02

Study summary

The present non-inferiority randomized controlled trial aims at comparing the efficacy of 6-month Good Psychiatric Management to 6-month Dialectical-Behavior Therapy for personality disorder (and borderline personality disorder). In addition, six mechanisms of change are systematically tested within a within- and between-person design. In-session physiology assesses the emotional engagement and non-verbal synchrony, while out-of-session self-report questionnaires (i.e., diary) assess generalized skills and capabilities.

03

Conditions studied

  • Borderline Personality Disorder
  • Moderate Personality Disorder
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Borderline Personality Disorder; Moderate Personality Disorder

Exclusion criteria

Exclusion Criteria:

  • neurological disorder; schizophrenia; self-reported cardiological diagnosis; self-reported pregnancy
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
144 participants (estimated)

Study arms

  • Experimental
    6 month Good Psychiatric Management

    Behavioral: Good Psychiatric Management

  • Active comparator
    6 month Dialectical Behavior Therapy

    Behavioral: dialectical behavior therapy

Interventions

  • BehavioralGood Psychiatric Management

    Use of interpersonal hypersensitivity model

  • Behavioraldialectical behavior therapy

    use of chain analyses and emotion regulation strategies according to protocol

06

What researchers measure

Primary outcomes

  1. ZAN-BPD

    Zanarini Borderline Personality Disorder Scale (Zanarini, 2003) ranges between 0 and 36, higher scores mean more symptom load (so worse outcome).

    Time frame: 6 months

07

Study locations

1 of 1 sites recruiting
  • Lausanne University Hospital
    Lausanne, Canton of Vaud 1004, Switzerland
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Dec 2029, 38 months after the start.

Of 105 non-industry interventional studies with no phase under Borderline Personality Disorder, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 54. This study's planned 38 months is close to that.

Counting every sponsor, half of 107 studies reached it within 35 months; a quarter within 24 and three quarters within 53.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 27, 2026
First posted
Nov 17, 2026
StartActual
Oct 1, 2026
Primary completionEst.
Dec 31, 2029
CompletionEst.
Aug 31, 2030
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940660
Responsible party
Ueli Kramer (Prof., University of Lausanne Hospitals) — Principal investigator
First posted
Nov 17, 2026
Start date
Oct 1, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Aug 31, 2030 (estimated)
Last update
Nov 17, 2026

Study contacts

Ueli Kramer, PhD
Contact
ueli.kramer@chuv.ch
0213140050

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion